Catalytic Properties of Botulinum Neurotoxin Subtypes A3 and A4

Overview

Journal Biochemistry

Specialty Biochemistry

Date 2009 Mar 5

PMID 19256469

Citations 30

Authors

James S Henkel

Mark Jacobson

William Tepp

Christina Pier

Eric A Johnson

Joseph T Barbieri

Affiliations

Soon will be listed here.

Abstract

Botulinum toxins (BoNT) are zinc proteases (serotypes A-G) which cause flaccid paralysis through the cleavage of SNARE proteins within motor neurons. BoNT/A was originally organized into two subtypes, BoNT/A1 and BoNT/A2, which are approximately 95% homologous and possess similar catalytic activities. Subsequently, two additional subtypes were identified, BoNT/A3 (Loch Maree) and BoNT/A4 (657Ba), which are 81 and 88% homologous with BoNT/A1, respectively. Alignment studies predicted that BoNT/A3 and BoNT/A4 were sufficiently different from BoNT/A1 to affect SNAP25 binding and cleavage. Recombinant light chain (LC) of BoNT/A3 (LC/A3) and BoNT/A4 (LC/A4) were subjected to biochemical analysis. LC/A3 cleaved SNAP25 at 50% of the rate of LC/A1 but cleaved SNAPtide at a faster rate than LC/A1, while LC/A4 cleaved SNAP25 and SNAPtide at slower rates than LC/A1. LC/A3 and LC/A4 had similar K(m) values for SNAP25 relative to LC/A1, while the k(cat) for LC/A4 was 10-fold slower than that for LC/A1, suggesting a defect in substrate cleavage. Neither LC/A3 nor LC/A4 possessed autocatalytic activity, a property of LC/A1 and LC/A2. Thus, the four subtypes of BoNT/A bind SNAP25 with similar affinity but have different catalytic capacities for SNAP25 cleavage, SNAPtide cleavage, and autocatalysis. The catalytic properties identified among the subtypes of LC/A may influence strategies for the development of small molecule or peptide inhibitors as therapies against botulism.

Citing Articles

The Use of Botulinum Toxin in Pre-Pubic Aponeurotic Complex Injuries: A Case Report.

Bisciotti G, Alessio A, Bisciotti A, Bisciotti A J Orthop Case Rep. 2024; 14(10):60-66.

PMID: 39381315 PMC: 11458203. DOI: 10.13107/jocr.2024.v14.i10.4812.

Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications.

Rasetti-Escargueil C, Palea S Toxins (Basel). 2024; 16(6).

PMID: 38922155 PMC: 11209287. DOI: 10.3390/toxins16060261.

Botulinum Neurotoxin A4 Has a 1000-Fold Reduced Potency Due to Three Single Amino Acid Alterations in the Protein Receptor Binding Domain.

Tepp W, Bradshaw M, Gardner A, Kaufman R, Barbieri J, Pellett S Int J Mol Sci. 2023; 24(6).

PMID: 36982762 PMC: 10055998. DOI: 10.3390/ijms24065690.

A Comprehensive Structural Analysis of Neurotoxin A Cell-Binding Domain from Different Subtypes.

Gregory K, Acharya K Toxins (Basel). 2023; 15(2).

PMID: 36828407 PMC: 9966434. DOI: 10.3390/toxins15020092.

Crystal structure of the catalytic domain of botulinum neurotoxin subtype A3.

Leka O, Wu Y, Li X, Kammerer R J Biol Chem. 2021; 296:100684.

PMID: 33891946 PMC: 8135040. DOI: 10.1016/j.jbc.2021.100684.

References

Chen S, Kim J, Barbieri J . Mechanism of substrate recognition by botulinum neurotoxin serotype A. J Biol Chem. 2007; 282(13):9621-9627. DOI: 10.1074/jbc.M611211200. View

Sikorra S, Henke T, Swaminathan S, Galli T, Binz T . Identification of the amino acid residues rendering TI-VAMP insensitive toward botulinum neurotoxin B. J Mol Biol. 2006; 357(2):574-82. DOI: 10.1016/j.jmb.2005.12.075. View

Schiavo G, Shone C, Bennett M, Scheller R, Montecucco C . Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins. J Biol Chem. 1995; 270(18):10566-70. DOI: 10.1074/jbc.270.18.10566. View

Hill K, Smith T, Helma C, Ticknor L, Foley B, Svensson R . Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol. 2006; 189(3):818-32. PMC: 1797315. DOI: 10.1128/JB.01180-06. View

Rigoni M, Caccin P, Johnson E, Montecucco C, Rossetto O . Site-directed mutagenesis identifies active-site residues of the light chain of botulinum neurotoxin type A. Biochem Biophys Res Commun. 2001; 288(5):1231-7. DOI: 10.1006/bbrc.2001.5911. View

Smith T, Lou J, Geren I, Forsyth C, Tsai R, LaPorte S . Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun. 2005; 73(9):5450-7. PMC: 1231122. DOI: 10.1128/IAI.73.9.5450-5457.2005. View

Lacy D, Stevens R . Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol. 1999; 291(5):1091-104. DOI: 10.1006/jmbi.1999.2945. View

Bandyopadhyay S, CLARK A, Dasgupta B, Sathyamoorthy V . Role of the heavy and light chains of botulinum neurotoxin in neuromuscular paralysis. J Biol Chem. 1987; 262(6):2660-3. View

Fang H, Luo W, Henkel J, Barbieri J, Green N . A yeast assay probes the interaction between botulinum neurotoxin serotype B and its SNARE substrate. Proc Natl Acad Sci U S A. 2006; 103(18):6958-63. PMC: 1447522. DOI: 10.1073/pnas.0510816103. View

10.

Ahmed S, Olson M, Ludivico M, Gilsdorf J, Smith L . Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity. Protein J. 2008; 27(3):151-62. DOI: 10.1007/s10930-007-9118-8. View

11.

Baldwin M, Tepp W, Przedpelski A, Pier C, Bradshaw M, Johnson E . Subunit vaccine against the seven serotypes of botulism. Infect Immun. 2007; 76(3):1314-8. PMC: 2258812. DOI: 10.1128/IAI.01025-07. View

12.

Chen S, Barbieri J . Unique substrate recognition by botulinum neurotoxins serotypes A and E. J Biol Chem. 2006; 281(16):10906-11. DOI: 10.1074/jbc.M513032200. View

13.

Schmidt J, Stafford R . Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity. Biochemistry. 2005; 44(10):4067-73. DOI: 10.1021/bi0477642. View

14.

Arndt J, Yu W, Bi F, Stevens R . Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition. Biochemistry. 2005; 44(28):9574-80. PMC: 2583140. DOI: 10.1021/bi0505924. View

15.

Schiavo G, Rossetto O, Santucci A, Dasgupta B, Montecucco C . Botulinum neurotoxins are zinc proteins. J Biol Chem. 1992; 267(33):23479-83. View

16.

Ahmed S, Byrne M, Jensen M, Hines H, Brueggemann E, Smith L . Enzymatic autocatalysis of botulinum A neurotoxin light chain. J Protein Chem. 2001; 20(3):221-31. DOI: 10.1023/a:1010952025677. View

17.

Foran P, Lawrence G, Shone C, Foster K, Dolly J . Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry. 1996; 35(8):2630-6. DOI: 10.1021/bi9519009. View

18.

Arndt J, Chai Q, Christian T, Stevens R . Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity. Biochemistry. 2006; 45(10):3255-62. DOI: 10.1021/bi052518r. View

19.

Lacy D, Tepp W, Cohen A, Dasgupta B, Stevens R . Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998; 5(10):898-902. DOI: 10.1038/2338. View

20.

Boldt G, Kennedy J, Hixon M, McAllister L, Barbieri J, Tzipori S . Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem. 2006; 8(4):513-21. PMC: 2644723. DOI: 10.1021/cc060010h. View